Switglim mp
Each uncoated bilayered tablet contains:glimepiride ip + pioglitazone hydrochloride ip eq. To pioglitazone + metformin hydrochloride ip(in sustained release form)
1 x 15 tab/ strip
Glimepiride stimulates insulin secretion from pancreatic beta cells by blocking atp-sensitive potassium channels, leading to increased insulin release. Pioglitazone enhances insulin sensitivity in muscle and adipose tissue by activating ppar-gamma receptors, promoting glucose uptake. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, these drugs lower blood glucose through increased insulin release, improved insulin action, and reduced glucose production
As prescribed by physician/ respective specialist or rmp
In the management of uncontrolled t2dm patients with insulin resistance
Common side effects of include low blood sugar (hypoglycaemia), nausea, diarrhoea, abdominal pain, constipation, and changes in taste
Glimepiride stimulates insulin secretion via closure of atp-sensitive potassium channels in beta cells.
metformin reduces hepatic glucose production, augments insulin sensitivity, and lowers intestinal glucose absorption. Pioglitazone enhances insulin sensitivity in muscle and adipose tissue by activating ppar-gamma receptors, promoting glucose uptake
